[Adjuvant chemotherapy in primary radically operated ovarian cancer].
There are no conclusive studies on the value of adjuvant chemotherapy in radical resected ovarian carcinoma. General reflections including parameters, toxicity and formation of a secondary tumor suggest forgoing adjuvant therapy of stages Ia to IIa. The survival rate of all other stages is below 50%. A therapy would seem necessary. Only general recommendations can be made due to lack of conclusive trials.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy; D011379:Prognosis
D000970:Antineoplastic Agents; D008558:Melphalan
Adjuvante Chemotherapie beim primär radikal operierten Ovarialkarzinom.